Welcome to our dedicated page for Protagenic SEC filings (Ticker: PTIXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTIXW SEC filings page is closely tied to the regulatory disclosures of Protagenic Therapeutics, Inc., whose common stock trades under the symbol PTIX on the Nasdaq Capital Market. While PTIXW itself represents publicly traded warrants, investors typically review the company’s broader SEC filings to understand how clinical progress, strategic transactions, and listing matters may affect both the common stock and the warrants.
Recent 8-K and 8-K/A filings provide detailed information on material events. One 8-K/A explains that on May 15, 2025, Protagenic Therapeutics entered into a Share Exchange Agreement with Alterola Biotech Inc., EMC2 Capital LLC, and the owners of Phytanix Bio, through which it acquired 100% of the issued and outstanding common shares of Phytanix Bio. The filing also notes that Phytanix Bio is treated as the accounting acquirer in a reverse acquisition under ASC 805-40 and describes five preclinical drug candidate assets (PHYX-001 through PHYX-005) obtained in the transaction.
Another 8-K describes a restructuring plan approved by the Board of Directors to transition to a virtual operating model, temporarily suspend expenditures on preclinical programs originating from Phytanix Bio, and focus capital on the company’s highest-priority clinical program or programs, including a Phase 2 clinical trial of PT00114. This filing also discusses changes in executive roles and the company’s intention to pursue strategic alternatives such as partnerships or out-licensing for the paused preclinical assets.
Additional filings, including Form 12b-25 (NT 10-Q) and 8-K reports on Nasdaq communications, outline delayed quarterly reporting related to merger and restructuring accounting, notices of non-compliance with listing rules, and subsequent steps taken to regain and maintain compliance. These documents explain how Protagenic Therapeutics manages its reporting obligations, capital structure, and listing status.
On this page, users can access these SEC filings and use AI-powered summaries to interpret complex sections such as reverse acquisition accounting, restructuring disclosures, and listing rule discussions. The filings also provide context for warrant-related terms originally set out in the company’s registration statements and prospectus for the PTIX and PTIXW offering.